The present invention relates to exosomes negative for the expression of CD99, that is, CD99- exosomes, characterized by specific molecular markers. Moreover, the present invention relates to a pharmaceutical composition which comprises said exosomes and the derived medical uses of said exosomes and/or of the composition.